ALIFE 2 Trial
ALIFE 2 is a multi-centre randomised controlled trial to compare low molecular weight heparin (LMWH) with standard pregnancy surveillance in improving the live birth rate in women with inherited thrombophilia and recurrent miscarriage (RM). Women with a history of RM (two or more not necessarily consecutive miscarriages or intra-uterine fetal deaths), confirmed inherited thrombophilia and who are attempting to conceive or are less than seven weeks pregnant (based on first day of last menstruation) will be registered onto the study and randomised to LMWH or standard pregnancy care. They are then followed up throughout pregnancy.
Alliance Pharmaceuticals Ltd is an international specialty pharma company headquartered in Chippenham, Wiltshire, UK. Alliance has launched the only licensed treatment, indicated for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management, into the UK this year. NVP is the most common condition in pregnancy, affecting up to 80% of all pregnant women [Royal College of Obstetricians and Gynaecologists Guidelines 2016]. For more information please visit the Alliance stand.
British Pregnancy Advisory Service
British Pregnancy Advisory Service is an independent reproductive healthcare charity which has, for 50 years, been providing services on behalf of the NHS to women and couples who want to prevent or end a pregnancy. We deliver and advocate for high quality, affordable care to almost 80,000 women per year. 96% of the women we care for have their treatment funded by the NHS. We have a national network of more than 70 clinics providing services on a locality basis from a variety of settings including dedicated clinics to services from GP practices. We are able to design and tailor services to meet the local needs. We are experts in our specialist area of healthcare and produce a wide variety of client and professional materials for you to use free of charge – visit www.bpas.org for more information.
Come and visit us on our stand.
Clearblue – SPD Swiss Precision Diagnostics GmbH, 1213 Petit Lancy, Geneva, Switzerland
Clearblue™ is the world’s No. 1 selling brand in home pregnancy and fertility tests*. Consumers trust the Clearblue brand because it delivers the accurate information they want. The Clearblue product range is built on a strong foundation of peer-reviewed science and consumer understanding. Clearblue is supported by over 30 years of expertise, quality and innovation in consumer diagnostics. * Based on international sales in nearly 20 countries compiled using independent market research data.
Established for over 50 years, Durbin works closely with international wholesalers/importers to source quality-assured pharmaceuticals that are not available locally. With a portfolio of over 20,000 products, we also supply consumables and medical equipment to over 180 countries worldwide, including the developing world and areas affected by natural disasters. With offices in the UK and USA our customers can enjoy a next-day delivery service as well as competitive freight rates.
GEM3 is a double blind placebo controlled trial offered to women receiving methotrexate for medical management of ectopic pregnancy. Recruited women receive routine care with methotrexate and are also randomised to either gefitinib or placebo (1:1). The primary aim is to reduce the need for ‘rescue surgery’ in women whom methotrexate has failed (15% of cases). We will also assess whether this combination can reduce the number of days to resolution of an ectopic pregnancy, prevent the need for a second dose of methotrexate and reduce the number of hospital visits, thus improving outcomes for women experiencing this difficult diagnosis.
Medicines & Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator of medicines, medical devices and blood components for transfusion. The MHRA is responsible for ensuring their safety, quality and effectiveness and helping to educate the public and healthcare professionals about the risks and benefits of medicines, medical devices and blood components, leading to safer and more effective use. The MHRA runs the Yellow Card reporting system for patients and healthcare professionals to report adverse incidents with medicines, medical devices, blood and counterfeit products.
The Miscarriage Association
Miscarriage can be a very distressing, frightening and lonely experience. The Miscarriage Association is a registered charity, providing support and information for anyone affected by miscarriage, ectopic or molar pregnancy. We also work with health professionals to promote best practice, support clinical and qualitative research and work to raise awareness of the facts and feelings of pregnancy loss.
National Early Pregnancy Clinical Trials Network
The aim of the National Early Pregnancy Clinical Trials Network is to bring together clinicians, academics, midwives, nurses, pharmacists, trial methodologists and patient representatives to deliver early pregnancy research. Collectively our national network now comprises more than 90 early pregnancy units across the UK, which are recruiting patients to NIHR-funded clinical trials. This network of units also works in conjunction with the Tommy’s National Centre for Miscarriage Research. Please visit our stand for more information about the MifeMiso trial which is currently recruiting and the PRISM and TABLET trials which are awaiting publication.
Pregnancy Sickness Support
Pregnancy Sickness Support is the national UK charity set up to support sufferers of nausea and vomiting in pregnancy and its severe form; Hyperemesis Gravidarum. Our work includes researching the cause and treatment of NVP and HG and producing educational and supportive information for sufferers, carers and health care professionals.
Quadratech Diagnostics distribute a range of tests for the determination of hCG (human Chorionic Gonadotropin) including the Check4® hCG(hl) termination of pregnancy test. This is not a classical home use pregnancy test. Check4® hCG(hl) is a low sensitivity, mid-stream urine test for the rapid determination of the hCG levels to confirm termination of pregnancy given under medical supervision. This is a popular choice for women who would prefer to avoid a second clinic visit when the test is negative, saving patient and clinical time.
For more information contact 03333212371 or [email protected]
At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalising healthcare. Siemens Healthineers new ultrasound product portfolio delivers a new era of imaging excellence. Our new ACUSON Juniper™ features a lightweight, ergonomic design with complete manoeuvrability for use across a wide variety of clinical segments. Though small in size, the ACUSON Juniper is powerful. The system’s versatility and adaptability makes it ideal for diverse patient anatomies and physiologies. To book a demo email [email protected] or visit www.siemens-healthineers.co.uk/ultrasound for more information and latest product line.